ReviewTrends in immunology2012
New directions in the basic and translational biology of interleukin-27.
Review in Trends in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Common Polymorphisms in IL-27 Genes May Contribute to Risk of Various Human Diseases in Asian Populations: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2016Pooled it
- Exogenous melatonin boosts vaccine-induced immunity in individuals with high pre-existing influenza immunity.Frontiers in immunology · 2025Trial
- Interleukin-27: a novel biomarker in predicting bacterial infection among the critically ill.Critical care (London, England) · 2015Trial
- Interleukins in Epilepsy: Friend or Foe.Neuroscience bulletin · 2024Review
- Enhanced cellular therapy: revolutionizing adoptive cellular therapy.Experimental hematology & oncology · 2024Review
- Multilevel omics for the discovery of biomarkers in pediatric sepsis.Pediatric investigation · 2023Review
- Article
- Anti-inflammatory cytokines in sickle cell disease.Molecular biology reports · 2022Review
- Kinase inhibition in autoimmunity and inflammation.Nature reviews. Drug discovery · 2021Review
- Interleukin-35 promotes the differentiation of regulatory T cells and suppresses Th2 response in IgG4-related type 1 autoimmune pancreatitis.Journal of gastroenterology · 2020Article
- Roles and Mechanisms of Interleukin-12 Family Members in Cardiovascular Diseases: Opportunities and Challenges.Frontiers in pharmacology · 2020Review
- The impact of vitamin D3 intake on inflammatory markers in multiple sclerosis patients and their first-degree relatives.PloS one · 2020Article
- Interleukin-27 Inhibits Trophoblast Cell Invasion and Migration by Affecting the Epithelial-Mesenchymal Transition in Preeclampsia.Reproductive sciences (Thousand Oaks, Calif.) · 2019Article
- Adult-derived human liver stem/progenitor cells as sensors of inflammation: a potential therapy for liver disorders.Hepatobiliary surgery and nutrition · 2019Article
- Fc gamma receptor IIa suppresses type I and III interferon production by human myeloid immune cells.European journal of immunology · 2018Article
- Interleukin 30 to Interleukin 40.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2018Review
- Interleukin-27 as a candidate diagnostic biomarker for bacterial infection in immunocompromised pediatric patients.PloS one · 2018Article
- Interleukin-27 Is a Potential Rescue Therapy for Acute Severe Colitis Through Interleukin-10-Dependent, T-Cell-Independent Attenuation of Colonic Mucosal Innate Immune Responses.Inflammatory bowel diseases · 2017Article
- Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47Scientific reports · 2017Article
- Emerging infection and sepsis biomarkers: will they change current therapies?Expert review of anti-infective therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Interleukin (IL)-27 is a member of the IL-6 and IL-12 family composed of the IL-27p28 and Epstein-Barr virus-induced gene 3 (EBI3) subunits. Although IL-27 was originally identified as a proinflammatory factor, subsequent studies have revealed the pleiotropic nature of this cytokine. This review discusses recent work that has explored the effect of IL-27 on CD4(+) T cell subsets, including T regulatory type 1 (Tr-1) cells, T follicular helper cells (Tfhs), and forkhead box P3 (Foxp3)(+) T regulatory cells (Tregs). Additionally, we highlight studies that have identified a role for the IL-27p28 subunit as a cytokine receptor antagonist. Much of the recent work on IL-27 has been relevant to human disease states characterized by inappropriate or excessive inflammation, and this review discusses potential opportunities to use IL-27 as a therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.